Shared Decision-Making Is Ours. Don't Let Them Break It.

Shared decision-making is a foundation of palliative care. It is how we do the work. Not a buzzword, not a philosophy elective, not a line item on a satisfaction survey—it is the substrate on which every goals-of-care conversation, every family meeting, every honest prognosis disclosure is built.

So when someone takes that phrase and hollows it out, palliative care clinicians should pay attention. Even—especially—when the hollowing is happening in a completely different clinical domain.

That is what is happening right now with childhood vaccines. And if you haven’t connected the dots to your practice yet, this piece is an invitation to do so before the damage arrives at your bedside.

What Happened

In January 2026, HHS Secretary Robert F. Kennedy Jr. bypassed his own vaccine advisory committee and dropped universal recommendations for hepatitis A, hepatitis B, influenza, meningococcal ACWY, and rotavirus vaccines. These vaccines did not become unavailable. They were not pulled from the market. They were reclassified: moved from “routine” to “shared clinical decision-making.”

On its face, the phrase sounds reasonable. It sounds like something we would say. That is the point.

The change was not backed by any new evidence. No study emerged showing these vaccines were less safe or less effective than they had been the day before. The reclassification was a policy decision dressed in clinical language, and the language was chosen with care. As Katherine Hall Jamieson of the Annenberg Public Policy Center put it, applying the “shared decision-making” label to thoroughly studied routine vaccines “suggests that the public health community has doubts about the safety and efficacy of these vaccines when it does not.”

The Annenberg Center followed up with survey data that should alarm anyone who depends on clinical language meaning what it says. In a nationally representative survey of 1,699 U.S. adults, one in five interpreted “shared decision-making” to mean the vaccine “may not be a good idea for everyone.” Over 40% believed it meant patients could make the decision without consulting a clinician at all. More than one in ten had no idea what it meant.

This is not a vaccine essay. It is a language essay. And the language being corrupted is ours.

What Shared Decision-Making Actually Is

The concept of shared decision-making emerged in the late 1980s as a corrective to decades of medical paternalism—an era when physicians made treatment decisions unilaterally, often without informing patients of alternatives or risks. Charles, Gafni, and Whelan formalized the framework in 1997: at minimum, both clinician and patient are involved, both share information, both take steps to build consensus, and an agreement is reached about treatment.

The critical piece—the one being deliberately obscured—is context. Shared decision-making was designed for preference-sensitive decisions: clinical situations where genuine equipoise exists between options, where the evidence does not clearly favor one path, and where the patient’s values and circumstances legitimately alter the calculus. Lumpectomy versus mastectomy. Dialysis versus conservative management. Chemotherapy cycle five versus comfort-focused care.

Jack Wennberg’s distinction between “effective care” and “preference-sensitive care” is the backbone here. Effective care is founded on evidence so strong that patients should always receive it when indicated. Preference-sensitive care describes situations where two or more valid approaches exist and the best choice depends on how the patient weighs the tradeoffs. SDM belongs in the latter. When you apply it to the former—when you impose the framework of uncertainty onto settled evidence—you are not empowering patients. You are manufacturing doubt.

Palliative care clinicians know this distinction in our bones. We live in it. The goals-of-care conversation is the highest-stakes version of shared decision-making in all of medicine, and we do it precisely because many end-of-life decisions involve genuine equipoise. There is no single right answer to “what matters most to you now.” That is why the framework exists.

The Playbook: Manufactured Epistemic Ambiguity

What MAHA has done is not new in structure. David Michaels documented the strategy in Doubt Is Their Product: when you cannot defeat the evidence, manufacture uncertainty about it. The tobacco industry pioneered this. The fossil fuel industry refined it. The playbook is always the same: introduce the appearance of scientific debate where no substantive debate exists, then use that appearance to justify inaction, delay, or policy retreat.

MAHA’s innovation is to execute this playbook using the language of patient-centered care rather than the language of industry lobbying. That makes it far more insidious, because it wraps the corrosion in a vocabulary that clinicians—especially palliative care clinicians—instinctively trust.

The prior instance of SDM applied to vaccines illustrates the contrast. In 2015, ACIP placed the meningococcal B vaccine in the shared clinical decision-making category for adolescents. That decision was based on specific clinical reasoning: the vaccine does not reduce bacterial carriage, meaning it offers individual protection without population-level transmission benefit. Genuine equipoise existed. Even so, the result was predictable: MenB vaccination coverage remained low, with only about 30% of 17-year-olds receiving a dose by 2022, compared with over 60% for the routinely recommended MenACWY. The SDM label itself depressed uptake—even when the underlying reasoning was scientifically sound.

Now apply that same label to vaccines where no such equipoise exists. The signal to the public is unmistakable: if the experts aren’t sure, why should I be?

Why Palliative Care Is Collateral Damage

Here is where palliative care clinicians need to stop reading this as a public health story and start reading it as a threat to their own clinical practice. The mechanisms of harm are specific and predictable.

Linguistic Contamination

SDM is not a trademarked term. It does not have a gatekeeper. When it becomes culturally coded as “the government is hiding something” or “this is a way to avoid giving you what works,” that coding does not confine itself to immunization clinics. It follows the phrase wherever it goes.

Now imagine a palliative care consultation where you say to a family: “I’d like us to make this decision together.” Or: “There are real tradeoffs here, and your mom’s values should drive the plan.” In a world where shared decision-making has been weaponized to mean the authorities want to withhold something from you, how does that land?

It lands as suspicion. It lands as: “Are you trying to talk us out of treatment?”

We already fight this perception. Palliative care has spent two decades pushing back against the myth that we are the “give up” team. The MAHA reframing of SDM does not create this problem from scratch. It pours accelerant on an existing fire.

Prognostic Honesty Becomes Suspect

One of the hardest things we do is tell someone the truth about their prognosis. We do it because patients and families deserve honest information to make decisions that reflect their actual values—not the values they would hold if they had better data. This requires trust: trust that the clinician is sharing evidence in good faith, not steering toward a predetermined outcome.

If MAHA’s framing teaches the public that any strong clinical recommendation is a power play rather than a professional responsibility, the foundation under prognostic disclosure erodes. “The evidence suggests this treatment is unlikely to help” becomes, to the suspicious ear, “They don’t want to give my mother a chance.”

The distinction between a recommendation and a coercion is the moral architecture of palliative care. When that distinction collapses in the broader culture, we lose the ground we stand on.

“Choice” Becomes Counter-Expertise

MAHA’s version of shared decision-making repositions patient choice not as informed deliberation but as resistance to expert opinion. Choice becomes virtuous precisely because it pushes back against what the clinician recommends. This is autonomy stripped of its informational foundation—what you might call autonomy as defiance.

In palliative care, this dynamic has specific consequences. Families who refuse hospice referrals not because they have weighed the evidence and preferred a different path, but because accepting a clinician’s recommendation feels like capitulation. Patients who insist on a sixth line of chemotherapy not because they understand the odds, but because “choosing to fight” has become a moral identity that the culture rewards. Surrogates who interpret comfort-focused care as coded abandonment.

None of this is hypothetical. We see it now. The MAHA reframing gives it cultural permission and rhetorical ammunition.

Comfort Care Gets Politicized

Follow the logic one more step. If “shared decision-making” becomes the public signal for “the government wants to withhold care,” and if palliative care’s clinical method is shared decision-making, then palliative care itself can be framed as a vehicle for rationing dressed in compassion. This is not a paranoid extrapolation. It is the structural conclusion of the rhetorical move MAHA has already made.

We have seen versions of this before—“death panels” was the last time palliative care got caught in someone else’s political crossfire. That phrase attached to advance care planning, not to SDM, but the mechanism was identical: take a clinical practice, reframe it as a government conspiracy to limit care, and watch trust erode.

Systems Start Hedging

If SDM becomes politically radioactive, expect institutional responses. Hospitals may dilute palliative care’s authority to make clear recommendations in order to avoid the appearance of coercion. States may adopt “shared decision-making mandates” that sound protective but function as impediments—requiring extensive documentation that a patient chose comfort care, turning every goals-of-care conversation into a liability exercise. Health systems already nervous about patient satisfaction scores may further erode the clinician’s ability to say, clearly and with conviction: “I recommend we stop this treatment.”

That recommendation—offered with evidence, compassion, and respect for the patient’s values—is the single most important thing palliative care does. Anything that makes it harder to deliver is a threat to the patients we serve.

What This Asks of Us

This is not a problem we can solve by ignoring it. The corruption of clinical language has downstream effects whether or not palliative care clinicians engage with the vaccine debate directly. The phrase is already contaminated. The question is what we do about it.

Name the framework explicitly, every time. Do not assume families know what you mean when you say “let’s make this decision together.” Define it. “What I mean by that is: I’m going to share what I know about your dad’s condition, you’re going to share what matters most to him, and together we’re going to build a plan that reflects both.” The days of relying on the phrase to do the work by itself may be behind us.

Distinguish recommendation from coercion—out loud. “I’m making a recommendation because the evidence is clear, and I think you deserve my honest assessment. But this is your decision, and I’ll support whatever you choose.” Name the clinician’s role as an act of responsibility, not authority. Make the structure visible.

Build institutional shields. Communication standards, documentation templates, and training curricula should explicitly define what SDM means in serious illness care—not because clinicians don’t know, but because institutions need a codified reference point when the term is contested from outside. If “shared decision-making” is going to be litigated in public, palliative care needs its definition on the record.

Do not let someone else’s misuse make us abandon the practice. The temptation will be to distance ourselves from the phrase. Rebrand. Call it something else. That instinct is wrong. SDM was built for the kind of work we do. If we surrender the term, we concede that the corruption is permanent. And we lose the decades of scholarship, training infrastructure, and public education that are anchored to it.

Where I Might Be Wrong

It is possible that the vaccine-SDM controversy will remain siloed—that the public will not generalize their suspicion of the term across clinical domains. People are capable of holding context-specific meanings for the same phrase. “Shared decision-making about vaccines” and “shared decision-making about whether to continue chemotherapy” may not register as the same concept in most people’s minds.

It is also possible that I am overweighting the speed of cultural transmission. Policy language often takes years to reshape public perception, and the MAHA movement’s influence may wane before the reframing fully takes hold.

And it is worth acknowledging that palliative care already operates in a low-trust environment for many patients—particularly communities of color, who have ample historical reason to distrust medical recommendations. For those communities, the MAHA reframing may add noise to a signal that was already scrambled. The incremental damage may be smaller than I’m suggesting. Or it may be larger, because it gives pre-existing distrust a new and culturally sanctioned vocabulary.

What I am confident about: the mechanism of harm is real, the direction is clear, and waiting to see if it materializes before responding is not a strategy. It is a gamble with other people’s suffering on the line.

The Word Matters

There is a sentence from the WIRED piece that has been rattling around in my head since I read it. Jake Scott, an infectious disease physician at Stanford, said that shared clinical decision-making “is being used as a political instrument to downgrade vaccines without explicitly banning them.” And then: “I think it’s worth watching where the template gets applied next.”

He is right. And palliative care should be watching, because we are downstream of this template whether we asked to be or not.

Shared decision-making in serious illness is not a hedge. It is not a bureaucratic cover for inaction. It is the most demanding form of clinical communication in medicine—requiring honesty about prognosis, courage to make recommendations, skill to elicit values, and discipline to let the patient’s priorities drive the plan even when you disagree.

It took decades to build the evidentiary, ethical, and educational infrastructure around that phrase. If we let it be hollowed out by people who are using it as a euphemism for policy retreat, we lose something that cannot be easily rebuilt.

Defend the meaning. Name it explicitly. Practice it with precision. And do not let someone else’s bad-faith use of the term make you flinch from the work it was built to support.

The patients who need us most are the ones for whom shared decision-making is not a slogan. It is the difference between dying in a way that reflects who they are—and dying in a way that reflects what the system decided for them.

That distinction is worth protecting.

For more on how palliative care approaches shared decision-making in serious illness, see the earlier pieces in the Beyond Mandatory Autonomy series: Part 1: Rethinking Decision-Making in Serious Illness and Part 2: Clinician-Guided Care Without Guilt.

I am a palliative care physician, educator, and professional strategery expert. Known for turning rounds into rants and rants into teaching points. Rounds & Rants represents my views — not those of any institution or professional membership organization where I hold a role. I don't write on their behalf and they don't vet what I publish.